ZA200709011B - Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer - Google Patents

Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Info

Publication number
ZA200709011B
ZA200709011B ZA200709011A ZA200709011A ZA200709011B ZA 200709011 B ZA200709011 B ZA 200709011B ZA 200709011 A ZA200709011 A ZA 200709011A ZA 200709011 A ZA200709011 A ZA 200709011A ZA 200709011 B ZA200709011 B ZA 200709011B
Authority
ZA
South Africa
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Application number
ZA200709011A
Other languages
English (en)
Inventor
Mcguigan Christopher
Mills Kenneth
Congiatu Constantino
Original Assignee
Cardiff Protides Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Protides Ltd filed Critical Cardiff Protides Ltd
Publication of ZA200709011B publication Critical patent/ZA200709011B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200709011A 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer ZA200709011B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds

Publications (1)

Publication Number Publication Date
ZA200709011B true ZA200709011B (en) 2009-01-28

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709011A ZA200709011B (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Country Status (20)

Country Link
US (1) US8263575B2 (xx)
EP (1) EP1866324B1 (xx)
JP (2) JP5345381B2 (xx)
CN (2) CN101175763A (xx)
AT (1) ATE471334T1 (xx)
AU (1) AU2006226182C1 (xx)
BR (1) BRPI0609704B8 (xx)
CA (1) CA2602324C (xx)
CY (1) CY1111538T1 (xx)
DE (1) DE602006014949D1 (xx)
DK (1) DK1866324T3 (xx)
ES (1) ES2348741T3 (xx)
GB (1) GB0505781D0 (xx)
IL (1) IL186104A (xx)
MX (1) MX2007011666A (xx)
PL (1) PL1866324T3 (xx)
PT (1) PT1866324E (xx)
SI (1) SI1866324T1 (xx)
WO (1) WO2006100439A1 (xx)
ZA (1) ZA200709011B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EA201100851A1 (ru) 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
PE20120013A1 (es) 2009-01-09 2012-02-02 Univ Cardiff Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012092484A2 (en) * 2010-12-29 2012-07-05 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
CN104974206B (zh) * 2011-03-01 2019-08-23 努卡那生物医药有限责任公司 用于治疗癌症的5-氟-2’-脱氧尿苷的氨基磷酸酯衍生物
WO2012125900A1 (en) 2011-03-16 2012-09-20 Enanta Pharmaceuticals, Inc. 2'-allene-substituted nucleoside derivatives
MX2015006195A (es) * 2012-11-16 2015-12-08 Univ Cardiff Procedimiento para preparar profarmacos de nucleosidos.
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
US20170101431A1 (en) * 2014-05-28 2017-04-13 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
AU2015352203B2 (en) 2014-11-28 2019-08-15 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
AU2016355429B2 (en) 2015-11-16 2021-05-06 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
CA2675757C (en) 1995-04-21 2011-03-15 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
DE69900841T2 (de) * 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) * 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
US20070265222A1 (en) * 2004-06-24 2007-11-15 Maccoss Malcolm Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物

Also Published As

Publication number Publication date
JP2013173786A (ja) 2013-09-05
AU2006226182B2 (en) 2011-09-01
JP5345381B2 (ja) 2013-11-20
MX2007011666A (es) 2007-11-14
AU2006226182A1 (en) 2006-09-28
EP1866324B1 (en) 2010-06-16
ES2348741T3 (es) 2010-12-13
DE602006014949D1 (de) 2010-07-29
CA2602324A1 (en) 2006-09-28
PL1866324T3 (pl) 2010-12-31
US8263575B2 (en) 2012-09-11
IL186104A (en) 2013-06-27
BRPI0609704A2 (pt) 2010-04-20
CN101175763A (zh) 2008-05-07
CA2602324C (en) 2015-02-24
JP5863702B2 (ja) 2016-02-17
CY1111538T1 (el) 2015-08-05
BRPI0609704B8 (pt) 2021-09-28
CN103936807A (zh) 2014-07-23
JP2008533191A (ja) 2008-08-21
DK1866324T3 (da) 2010-09-27
SI1866324T1 (sl) 2010-10-29
WO2006100439A1 (en) 2006-09-28
ATE471334T1 (de) 2010-07-15
BRPI0609704B1 (pt) 2020-12-01
EP1866324A1 (en) 2007-12-19
PT1866324E (pt) 2010-09-16
US20090215715A1 (en) 2009-08-27
GB0505781D0 (en) 2005-04-27
AU2006226182C1 (en) 2012-06-14
IL186104A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
SG164368A1 (en) Treatment of cancer
MY146112A (en) Long-term feed - cancer patient
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
TW200612918A (en) Lonidamine analogs
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX2010001821A (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
MX2009010899A (es) Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas.
TW200716141A (en) Compositions and methods for treatment for neoplasms
TW200737269A (en) Ion sources, systems and methods
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
TW200637522A (en) Skin treatment articles and methods
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
MY147247A (en) Organic compounds and their uses
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
MY166063A (en) Intravenous antiviral treatments